Results from promising human trials offer hope for tumour treatment
The Palin Communications team has been helping long term client, Australian life sciences company QBiotics, report good progress in developing EBC-46 as a potential local treatment for solid tumours in humans.
QBiotics is a public, unlisted company based in Brisbane, Queensland. EBC-46 is a novel compound with anticancer properties that is derived from a plant unique to Australia’s tropical rainforest.
Now, a multi-centre human trial is showing encouraging results and Palin supported QBiotics to implement a proactive media relations program leveraging the results. The PR coincided with (and supported) another round of successful capital raising for the company in late August.